

Interleukin-6 Receptor Antagonists in Critically Ill Patients

New England Journal of Medicine

385, 1147-1149

DOI: [10.1056/nejmc2108482](https://doi.org/10.1056/nejmc2108482)

Citation Report

#	ARTICLE	IF	CITATIONS
2	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <i>ELife</i> , 2021, 10, .	2.8	23
3	Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab. <i>Clinical Infectious Diseases</i> , 2022, 74, 1504-1504.	2.9	2
4	SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines. <i>Osteopathic Family Physician</i> , 2021, 13, .	0.2	0
6	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 623-628.	0.9	5
7	Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series. <i>AIDS Research and Therapy</i> , 2022, 19, 6.	0.7	4
8	A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 Signaling and Cellular Infection with SARS-CoV-2. <i>Journal of Virology</i> , 2022, 96, JVI0162221.	1.5	5
9	A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. , 2022, 4, e0662.		23
10	WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. <i>Journal of General Internal Medicine</i> , 2022, 37, 1980-1987.	1.3	27
11	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nature Communications</i> , 2022, 13, 2583.	5.8	25
12	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
13	Levilimab and baricitinib prescribing experience in outpatient COVID-19 patientsâ€™ treatment. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 668-674.	0.2	3
14	An autopsy case of COVID-19 with a sudden death: Clinicopathological comparison. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	3
15	Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 1082-1087.	0.5	3
16	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. <i>Cancers</i> , 2022, 14, 3711.	1.7	6
17	The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
19	Eosinophil Levels, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio in the Cytokine Storm Period of Patients with COVID-19. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-6.	0.8	5
20	COVID-19-associated fungal infections. <i>Nature Microbiology</i> , 2022, 7, 1127-1140.	5.9	183
21	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222.	0.8	3

#	ARTICLE	IF	CITATIONS
22	Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4758.	0.3	2
23	COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports. <i>Journal of Clinical Medicine</i> , 2022, 11, 5519.	1.0	12
24	Obesity and coronavirus disease 2019. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 207-218.	1.0	3
26	Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, .	4.7	19
27	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1119-1128.	5.2	4
28	Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study. <i>Vaccines</i> , 2022, 10, 1786.	2.1	6
29	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
30	Digital Protein Detection in Bulk Solutions. <i>ACS Omega</i> , 2022, 7, 37714-37723.	1.6	1
31	Treatment of severe COVID-19: an evolving paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1887-1891.	0.9	5
32	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	3
33	Computational search for potential COVID-19 drugs from ayurvedic medicinal plants to identify potential inhibitors against SARS-CoV-2 targets. <i>Current Computer-Aided Drug Design</i> , 2022, 19, .	0.8	1
34	COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study. <i>Annals of Medicine</i> , 2023, 55, 12-23.	1.5	3
35	A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 518-527.	2.3	5
36	Fire in the belly: A scoping review of the immunopathological mechanisms of acute pancreatitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
37	Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 119-121.	1.1	4
38	Maternal and Fetal Outcome in Pregnant Women With Critical COVID-19 Treated With Tocilizumab in a Tertiary Care Hospital in Dubai. <i>Cureus</i> , 2023, , .	0.2	0
39	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. <i>Thorax</i> , 2023, 78, 816-824.	2.7	3
40	Targeting IL-6 trans-signalling: past, present and future prospects. <i>Nature Reviews Immunology</i> , 2023, 23, 666-681.	10.6	46

#	ARTICLE	IF	CITATIONS
41	The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 147-163.	0.5	7
42	In the SARS-CoV-2 Pandora Pandemic: Can the Stance of Premorbid Intestinal Innate Immune System as Measured by Fecal Adnab-9 Binding of p87:Blood Ferritin, Yielding the FERAD Ratio, Predict COVID-19 Susceptibility and Survival in a Prospective Population Database?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7536.	1.8	2
43	COVID-19 and Multiorgan Response: The Long-Term Impact. <i>Current Problems in Cardiology</i> , 2023, 48, 101756.	1.1	2